Intra-Cellular Therapies Inc. (NASDAQ:ITCI) reported Q2 2017 earnings this Morning, coming in at ($0.41) per share, beating Wall Street’s estimates of ($0.78) per Share. Revenue for the quarter came in at $0.11 million beating analyst estimates of $0.03 million
Analyst Coverage For Intra-Cellular Therapies Inc. (NASDAQ:ITCI)
These are 5 Hold Ratings, 4 Buy Ratings .
The current consensus rating for Intra-Cellular Therapies Inc. (NASDAQ:ITCI) is Hold (Score: 2.44) with a consensus target price of $26.17 , a potential (142.51% upside)Recent Insider Trading for Intra-Cellular Therapies Inc. (NASDAQ:ITCI)
- On 1/5/2017 Lawrence J Hineline, VP, sold 1,918 with an average share price of $16.58 per share and the total transaction amounting to $31,800.44.
- On 1/5/2017 Michael Halstead, SVP, sold 1,601 with an average share price of $16.55 per share and the total transaction amounting to $26,496.55.
- On 1/5/2017 Sharon Mates, Chairman, sold 4,081 with an average share price of $16.55 per share and the total transaction amounting to $67,540.55.
- On 12/15/2016 Kimberly E Vanover, SVP, sold 9,375 with an average share price of $15.23 per share and the total transaction amounting to $142,781.25.
- On 12/7/2016 Alafi Capital Co Llc, Major Shareholder, bought 65,000 with an average share price of $16.27 per share and the total transaction amounting to $1,057,550.00.
- On 11/14/2016 Christopher D Alafi, Director, bought 34,000 with an average share price of $14.50 per share and the total transaction amounting to $493,000.00.
Recent Trading for Intra-Cellular Therapies Inc. (NASDAQ:ITCI) Shares of Intra-Cellular Therapies Inc. closed the previous trading session at 10.38 down -0.41 -3.85% with 275,024 shares trading hands.